In cell culture-based experiments we show that the resistance to ruxolitinib is mediated by secondary mutations in the kinase domain of JAK2, however, these secondary mutations are yet to be identified in MPN patients. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.